Search

Displaying results 2381 - 2390 of 4190 in total
  1. Drug

    Sarcosine

    go.drugbank.com/drugs/DB12519
    Investigational

    Sarcosine has been investigated for the treatment of Schizophrenia.

  2. Drug

    CP-609754

    go.drugbank.com/drugs/DB12640
    Investigational

    LNK 754 has been investigated in Mild Alzheimer's Disease.

  3. Drug

    Pyronaridine

    go.drugbank.com/drugs/DB12975
    Investigational

    Pyronaridine has been investigated for the treatment of Malaria.

  4. Drug

    Huperzine B

    go.drugbank.com/drugs/DB03348
    Experimental

    Huperzine B is a novel acetylcholinesterase inhibitor.

  5. Target

    Phosphoglycerate kinase 1

    go.drugbank.com/bio_entities/BE0004454
    TargetEnzymeHumans

    Catalyzes one of the two ATP producing reactions in the glycolytic pathway via the reversible conversion of 1,3-diphosphoglycerate to 3-phosphoglycerate (PubMed:30323285, PubMed:7391028). Both L- and D- forms of purine and pyrimidine nuc...

    Synonyms: Cell migration-inducing gene 10 protein
  6. Drug

    SBT101

    go.drugbank.com/drugs/DB18139
    Investigational

    ) gene. … SBT101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) gene therapy vector containing the human adenosine triphosphate (ATP)-binding cassette (ABC) sub-family D member 1 (ABCD1

  7. Drug

    Liposomal prostaglandin E1

    go.drugbank.com/drugs/DB05391
    Investigational

    Liposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent. The liposomal formulation of PGE-1 changes the drug’s dynami...

  8. Drug

    Piribedil

    go.drugbank.com/drugs/DB12478
    Investigational

    Piribedil has been investigated in Parkinson's Disease.

  9. Drug

    Aleplasinin

    go.drugbank.com/drugs/DB12635
    Investigational

    Aleplasinin has been investigated in Alzheimer Disease.

  10. Drug

    Ramucirumab

    go.drugbank.com/drugs/DB05578
    ApprovedInvestigational

    Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevent...